{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-017134","form_type":"8-K","ticker":"LIMN","cik":"0001971387","company_name":"Liminatus Pharma, Inc.","filed_at":"2026-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.906856+00:00","generated_at":"2026-05-16T02:10:31.959263+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Liminatus Pharma prices $4.0M public offering of common stock and warrants","bullets":["Offering of 13.8M shares/pre-funded warrants and warrants for up to 20.7M shares at combined $0.29 per unit.","Gross proceeds ~$4.0M; net proceeds ~$3.46M after placement agent fees and expenses.","Warrants exercisable immediately at $0.29 per share, expire 5 years from issuance.","Placement agent Maxim Group LLC receives 8% cash fee, $100K expense reimbursement, and 690,650 warrant shares at $0.319.","Directors and officers subject to 180-day lock-up; company restricted from certain equity issuances for 180 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-017134","json":"https://secwatch.observer/filing/0001104659-26-017134.json","markdown":"https://secwatch.observer/filing/0001104659-26-017134.md","text":"https://secwatch.observer/filing/0001104659-26-017134.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926017134/0001104659-26-017134-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926017134/tm266571d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:10:31.959263+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9255b1ced023d08a9c69e213cbee8c7af389aed9","claim":"Liminatus Pharma, Inc. entered into Purchase Agreement with certain purchasers party thereto (effective 2026-02-17).","evidence_excerpt":"the Company entered into a securities purchase agreement (the \"Purchase Agreement\") with certain purchasers party thereto.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926017134/0001104659-26-017134-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain purchasers party thereto"},{"label":"Effective","value":"2026-02-17"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}